As AR is essential for the development of prostate cancer, and EGFR is a key factor for definite lung cancer, future research will be indispensable to pay attention to the stratification of patients before the application of Hsp90-Cdc37-client protein targeted therapy. This evidence concerns the gene HSP90AA1 and Familial prostate cancer.